Overview

The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life

Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study will address whether the additional use of Ferric Derisomaltose on top of standard care will improve exercise capacity and quality of life in patients with acute heart failure and iron deficiency. One group of participants will receive treatment with Ferric Derisomaltose and the other group will receive normal saline 0.9% as placebo.
Phase:
Phase 4
Details
Lead Sponsor:
China-Japan Friendship Hospital